Story
Sionna Therapeutics Stock Plummets 92% After Cystic Fibrosis Drug Fails Mid-Stage Trial

Shares of Sionna Therapeutics collapsed by more than 92% in morning trading after the company announced its lead cystic fibrosis drug candidate, SION-719, failed to show any meaningful benefit in a Phase 2a clinical trial. The company confirmed it will not advance the development of the drug as an add-on to the current standard of care.
Clinical Trial Failure
Topline data from the PreciSION CF study showed that SION-719, when added to Vertex Pharmaceuticals' market-leading drug Trikafta, did not significantly improve CFTR protein function. The primary endpoint, a measure of sweat chloride concentration, showed a placebo-adjusted change of just -1.0 mmol/L, a result the company described as statistically indistinguishable from placebo.
Analysts had widely considered a reduction of at least 10 mmol/L to be a conservative benchmark for success. The trial was a randomized, double-blind, placebo-controlled crossover study involving 15 patients with cystic fibrosis.
Market Reaction and Analyst Downgrades
The clinical failure prompted a severe market sell-off and swift action from Wall Street analysts. The stock hit a new 52-week low of $4.01 as investors rapidly reassessed the company's prospects.
Key analyst actions included:
Ad- Wedbush: Downgraded Sionna from Outperform to Neutral and slashed its price target from $53 to $5.
- Stifel: Cut its rating from Buy to Hold and reduced its price target from $55 to $7, calling the outcome an "unequivocal failure."
In contrast, shares of competitor Vertex Pharmaceuticals (VRTX) rose on the news. The failure of SION-719 removes a potential near-term competitive threat to its dominant Trikafta franchise in the cystic fibrosis market.
Company Outlook
With its lead asset now shelved, investor focus shifts to Sionna's earlier-stage programs, particularly the SION-451 dual combination therapy. However, meaningful clinical data from this program is not expected for a considerable time.
Sionna reported ending the second quarter with approximately $268.3 million in cash and equivalents. The company announced it plans to preserve capital while it evaluates the next steps for its remaining pipeline.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.